A combination of a DNA-chimera siRNA against PLK-1 and zoledronic acid suppresses the growth of malignant mesothelioma cells in vitro

Cancer Letters

Volumn 294, Issue 2, 2010, Pages 245-253

  Kawata, Eri ^a,b   Ashihara, Eishi ^a   Nakagawa, Yoko ^a   Kiuchi, Takahiro ^a   Ogura, Mai ^a   Yao, Hisayuku ^a   Sakai, Kazuki ^a   Tanaka, Ruriko ^a   Nagao, Rina ^a   Yokota, Asumi ^a   Takeuchi, Miki ^a   Kimura, Shinya ^c   Hirai, Hideyo ^a   Maekawa, Taira ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b KYOTO SECOND RED CROSS HOSPITAL   (Japan)

^c SAGA UNIVERSITY   (Japan)

Author keywords

Bisphosphonate; DNA chimeric siRNA; Malignant mesothelioma; PLK 1; RNA interference

Indexed keywords

POLO LIKE KINASE 1; SMALL INTERFERING RNA; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG POTENTIATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALIGNANT MESOTHELIOMA; MITOSIS INHIBITION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA INTERFERENCE;

ANIMALS; APOPTOSIS; CELL CYCLE PROTEINS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CHIMERA; COMBINED MODALITY THERAPY; DIPHOSPHONATES; DNA; GENE THERAPY; HUMANS; IMIDAZOLES; MESOTHELIOMA; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 77953359872     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.02.008     Document Type: Article

References (54)

1. Robinson B.W., Lake R.A. Advances in malignant mesothelioma. New Engl. J. Med. 2005, 353:1591-1603.
2. Halstead J.C., Lim E., Venkateswaran R.M., Charman S.C., Goddard M., Ritchie A.J. Improved survival with VATS pleurectomy-decortication in advanced malignant mesothelioma. Eur. J. Surg. Oncol. 2005, 31:314-320.
3. Waller D.A. Malignant mesothelioma - British surgical strategies. Lung Cancer 2004, 45(Suppl 1):S81-S84.
4. Carteni G., Manegold C., Garcia G.M., Siena S., Zielinski C.C., Amadori D., Liu Y., Blatter J., Visseren-Grul C., Stahel R. Malignant peritoneal mesothelioma - results from the international expanded access program using pemetrexed alone or in combination with a platinum agent. Lung Cancer 2009, 64:211-218.
5. Taylor P., Castagneto B., Dark G., Marangolo M., Scagliotti G.V., van Klaveren R.J., Labianca R., Serke M., Schuette W., van Meerbeeck J.P., Heigener D., Liu Y., Adachi S., Blatter J., von Pawel J. Single-agent pemetrexed for chemonaive and pretreated patients with malignant pleural mesothelioma: results of an international expanded access program. J. Thorac. Oncol. 2008, 3:764-771.
6. Baas P., Ardizzoni A., Grossi F., Nackaerts K., Numico G., Van Marck E., van de Vijver M., Monetti F., Smid-Geirnaerdt M.J., van Zandwijk N., Debruyne C., Legrand C., Giaccone G. The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992). Eur. J. Cancer 2003, 39:353-357.
7. van Meerbeeck J.P., Gaafar R., Manegold C., Van Klaveren R.J., Van Marck E.A., Vincent M., Legrand C., Bottomley A., Debruyne C., Giaccone G. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J. Clin. Oncol. 2005, 23:6881-6889.
8. Lee C.W., Murray N., Anderson H., Rao S.C., Bishop W. Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia. Lung Cancer 2009, 64:308-313.
9. Aelony Y. Raltitrexed and pemetrexed studies in mesothelioma have not shown improved quality of life nor prolonged survival compared with effective pleurodesis with thoracoscopic talc poudrage. J. Clin. Oncol. 2006, 24:4667. (author reply 4667-4668).
10. Bumcrot D., Manoharan M., Koteliansky V., Sah D.W. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat. Chem. Biol. 2006, 2:711-719.
11. E. Ashihara, E. Kawata, T. Maekawa, Future prospect of RNA interference for cancer therapies, Curr. Drug Targets. in press.
12. Boutla A., Delidakis C., Livadaras I., Tsagris M., Tabler M. Short 5'-phosphorylated double-stranded RNAs induce RNA interference in Drosophila. Curr. Biol. 2001, 11:1776-1780.
13. Ui-Tei K., Naito Y., Zenno S., Nishi K., Yamato K., Takahashi F., Juni A., Saigo K. Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect. Nucleic Acids Res. 2008, 36:2136-2151.
14. Elbashir S.M., Martinez J., Patkaniowska A., Lendeckel W., Tuschl T. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. Embo. J. 2001, 20:6877-6888.
15. Barr F.A., Sillje H.H., Nigg E.A. Polo-like kinases and the orchestration of cell division. Nat. Rev. Mol. Cell Biol. 2004, 5:429-440.
16. van de Weerdt B.C., Medema R.H. Polo-like kinases: a team in control of the division. Cell Cycle 2006, 5:853-864.
17. Strebhardt K., Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat. Rev. Cancer 2006, 6:321-330.
18. Takai N., Hamanaka R., Yoshimatsu J., Miyakawa I. Polo-like kinases (Plks) and cancer. Oncogene 2005, 24:287-291.
19. Nogawa M., Yuasa T., Kimura S., Tanaka M., Kuroda J., Sato K., Yokota A., Segawa H., Toda Y., Kageyama S., Yoshiki T., Okada Y., Maekawa T. Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J. Clin. Invest. 2005, 115:978-985.
20. Kawata E., Ashihara E., Kimura S., Takenaka K., Sato K., Tanaka R., Yokota A., Kamitsuji Y., Takeuchi M., Kuroda J., Tanaka F., Yoshikawa T., Maekawa T. Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer. Mol. Cancer Ther. 2008, 7:2904-2912.
21. Schoffski P. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 2009, 14:559-570.
22. Mross K., Frost A., Steinbild S., Hedbom S., Rentschler J., Kaiser R., Rouyrre N., Trommeshauser D., Hoesl C.E., Munzert G. Phase I dose escalation and pharmacokinetic study of BI 2536, a novel polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 2008, 26:5511-5517.
23. Spankuch-Schmitt B., Bereiter-Hahn J., Kaufmann M., Strebhardt K. Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J. Natl. Cancer Inst. 2002, 94:1863-1877.
24. Yuasa T., Kimura S., Ashihara E., Habuchi T., Maekawa T. Zoledronic acid - a multiplicity of anti-cancer action. Curr. Med. Chem. 2007, 14:2126-2135.
25. Green J.R. Bisphosphonates: preclinical review. Oncologist 2004, 9(Suppl 4):3-13.
26. Kuroda J., Kimura S., Segawa H., Kobayashi Y., Yoshikawa T., Urasaki Y., Ueda T., Enjo F., Tokuda H., Ottmann O.G., Maekawa T. The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate. Blood 2003, 102:2229-2235.
27. Matsumoto S., Kimura S., Segawa H., Kuroda J., Yuasa T., Sato K., Nogawa M., Tanaka F., Maekawa T., Wada H. Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer 2005, 47:31-39.
28. Yuasa T., Nogawa M., Kimura S., Yokota A., Sato K., Segawa H., Kuroda J., Maekawa T. A third-generation bisphosphonate, minodronic acid (YM529), augments the interferon alpha/beta-mediated inhibition of renal cell cancer cell growth both in vitro and in vivo. Clin. Cancer Res. 2005, 11:853-859.
29. Horie N., Murata H., Nishigaki Y., Matsui T., Segawa H., Nogawa M., Yuasa T., Kimura S., Maekawa T., Fushiki S., Kubo T. The third-generation bisphosphonates inhibit proliferation of murine osteosarcoma cells with induction of apoptosis. Cancer Lett. 2006, 238:111-118.
30. Sato K., Yuasa T., Nogawa M., Kimura S., Segawa H., Yokota A., Maekawa T. A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo. Brit. J. Cancer 2006, 95:1354-1361.
31. Chou T.C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010, 70:440-446.
32. Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 2006, 58:621-681.
33. Kimura S., Kuroda J., Segawa H., Sato K., Nogawa M., Yuasa T., Ottmann O.G., Maekawa T. Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines. Int. J. Hematol. 2004, 79:37-43.
34. Temmink O.H., Hoebe E.K., van der Born K., Ackland S.P., Fukushima M., Peters G.J. Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells. Brit. J. Cancer 2007, 96:231-240.
35. Keshelava N., Davicioni E., Wan Z., Ji L., Sposto R., Triche T.J., Reynolds C.P. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide. J. Natl. Cancer Inst. 2007, 99:1107-1119.
36. Sei S., Mussio J.K., Yang Q.E., Nagashima K., Parchment R.E., Coffey M.C., Shoemaker R.H., Tomaszewski J.E. Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells. Mol. Cancer 2009, 8:47.
37. Reszka A.A., Halasy-Nagy J., Rodan G.A. Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol. Pharmacol. 2001, 59:193-202.
38. Dai B.N., Yang Y., Chau Z., Jhanwar-Uniyal M. Polo-like kinase 1 regulates RhoA during cytokinesis exit in human cells. Cell Proliferat. 2007, 40:550-557.
39. Burkard M.E., Randall C.L., Larochelle S., Zhang C., Shokat K.M., Fisher R.P., Jallepalli P.V. Chemical genetics reveals the requirement for polo-like kinase 1 activity in positioning RhoA and triggering cytokinesis in human cells. Proc. Natl. Acad. Sci. USA 2007, 104:4383-4388.
40. Zelphati O., Szoka F.C. Mechanism of oligonucleotide release from cationic liposomes. Proc. Natl. Acad. Sci. USA 1996, 93:11493-11498.
41. Choung S., Kim Y.J., Kim S., Park H.O., Choi Y.C. Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochem. Biophys. Res. Commun. 2006, 342:919-927.
42. Behlke M.A. Chemical modification of siRNAs for in vivo use. Oligonucleotides 2008, 18:305-319.
43. Chia W.J., Tang B.L. Emerging roles for Rab family GTPases in human cancer. Biochim. Biophys. Acta 2009, 1795:110-116.
44. Hattori M., Minato N. Rap1 GTPase: functions, regulation, and malignancy. J. Biochem. 2003, 134:479-484.
45. Fehrenbacher N., Bar-Sagi D., Philips M. Ras/MAPK signaling from endomembranes. Mol. Oncol. 2009, 3:297-307.
46. Koto K., Horie N., Kimura S., Murata H., Sakabe T., Matsui T., Watanabe M., Adachi S., Maekawa T., Fushiki S., Kubo T. Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model. Cancer Lett. 2009, 274:271-278.
47. Yano S., Zhang H., Hanibuchi M., Miki T., Goto H., Uehara H., Sone S. Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice. Clin. Cancer Res. 2003, 9:5380-5385.
48. Hiraga T., Williams P.J., Ueda A., Tamura D., Yoneda T. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin. Cancer Res. 2004, 10:4559-4567.
49. Merrell M.A., Wakchoure S., Ilvesaro J.M., Zinn K., Gehrs B., Lehenkari P.P., Harris K.W., Selander K.S. Differential effects of Ca(2+) on bisphosphonate-induced growth inhibition in breast cancer and mesothelioma cells. Eur. J. Pharmacol. 2007, 559:21-31.
50. Wakchoure S., Merrell M.A., Aldrich W., Millender-Swain T., Harris K.W., Triozzi P., Selander K.S. Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo. Clin. Cancer Res. 2006, 12:2862-2868.
51. Raizon A., Schwartz A., Hix W., Rockoff S.D. Calcification as a sign of sarcomatous degeneration of malignant pleural mesotheliomas: a new CT finding. J. Comput. Assist. Tomogr. 1996, 20:42-44.
52. Liu F., Misra P., Lunsford E.P., Vannah J.T., Liu Y., Lenkinski R.E., Frangioni J.V. A dose- and time-controllable syngeneic animal model of breast cancer microcalcification. Breast Cancer Res. Treat. 2009.
53. Barr F.A., Gruneberg U. Cytokinesis: placing and making the final cut. Cell 2007, 131:847-860.
54. Yoshida S., Bartolini S., Pellman D. Mechanisms for concentrating Rho1 during cytokinesis. Genes Dev. 2009, 23:810-823.